SCHEMBL3097005

SCHEMBL3097005

O=C(O)C(Cc1ccc(Cl)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1.[Na].[Na]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.53
KAT6A Q92794 3/20 0.52
F2 P00734 2/20 0.48
ADAMTS5 Q9UNA0 1/20 0.48
MMP2 P08253 1/20 0.48
EGFR P00533 2/20 0.48
ERBB2 P04626 2/20 0.48
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
LMNA P02545 1/20 0.46
BCL2 P10415 1/20 0.45
ALDH1A1 P00352 1/20 0.45
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
BCL2L1 Q07817 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091186 1.00 LARS1 (0.53) LARS1KAT6AF2ADAMTS5MMP2
SCHEMBL3096994 0.99 LARS1 (0.52) LARS1KAT6AF2ADAMTS5MMP2
SCHEMBL3090840 0.91 LARS1 (0.58) LARS1KAT6AF2MMP2SLC1A3
SCHEMBL3096998 0.91 LARS1 (0.51) LARS1KAT6AF2ADAMTS5MMP2
SCHEMBL3090045 0.90 LARS1 (0.57) LARS1KAT6AF2SLC1A3SLC1A2
SCHEMBL3103948 0.89 KAT6A (0.55) LARS1KAT6AF2ADAMTS5MMP2
SCHEMBL3103901 0.89 PPARG (0.53) LARS1KAT6AF2EGFRERBB2
SCHEMBL3092119 0.88 KAT6A (0.51) LARS1KAT6AF2SLC1A3SLC1A2
SCHEMBL3088714 0.86 KDM4E (0.58) LARS1KAT6AF2MMP2EGFR
SCHEMBL15000247 0.86 LARS1 (0.49) LARS1KAT6AF2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885KAT6A 3337/4885F2 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.